CARASENT ASA: APPROVED PROSPECTUS AND LISTING OF SHARES NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, SOUTH AFRICA, NEW ZEALAND, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, May 25, 2021: Reference is made to the stock exchange announcement on December 11, 2020 where Carasent ASA (the "Company") announced that the Company had resolved a private placement in connection with the acquisition of Avans Soma AS (the “Private Placement”) The Private Placement was directed towards the shareholders (sellers) of Avans Soma as consideration for 50 % of the shares in Avans Soma AS and comprised of 2,211,191 new shares (the “New Shares”). The New Shares were registered on delivered on a separate ISIN NO 001 0915499 (temporary ISIN) and was unlisted pending approval of a listing prospectus (the “Prospectus”) by the Norwegian Financial Supervisory Authority (the “NFSA”). The NFSA has reviewed and approved the Company's prospectus on May 25, 2021 regarding the listing of the New Shares. Following the NSFA approval of the Prospectus, the New Shares will be transferred to the Company’s ordinary ISIN and will be listed on the Oslo Stock Exchange. The Prospectus will be made available at: www.carasent.com. The Prospectus will also be available at the offices of the Company. For further information, please contact: Johan Lindqvist, Chairman johan.lindqvist@windchange.se +46 733 55 09 35
